-- 週一下午晚些時候，科技股漲跌互現，道富科技精選行業SPDR ETF (XLK)上漲0.2%，道富SPDR標普半導體ETF (XSD)下跌0.4%。 費城半導體指數下跌0.5%。 公司新聞方面，根據彭博社報道，蘋果公司(AAPL)計劃在其下一次iPhone軟體更新中推出一項新功能，允許用戶在「錢包」應用程式中創建和個性化自己的電子票據和禮品卡。報導稱，iOS 27「錢包」應用程式的這項通行證創建功能有望解決許多服務仍無法提供與「錢包」平台相容的通行證的問題。蘋果股價下跌1.1%。
Related Articles
Mining & Metals
PJX Resources Adopting Semi-Annual Financial Reporting
$PJX.V
Australia
Lattice Semiconductor to Acquire AMI for $1.65 Billion in Cash and Stock From THL Partners
Lattice Semiconductor (LSCC) agreed to acquire AMI, a cloud and AI-server management software company, for $1.65 billion in cash and stock from THL Partners.The purchase includes $1 billion in cash and $650 million in Lattice stock. The acquisition is expected to close in Q3, subject to regulatory approvals and other conditions, Lattice said Monday in a statement.The transaction is expected to be accretive to gross margin, free cash flow and earnings per share on an adjusted basis, and AMI is projected to generate more than $200 million in revenue in 2026, Lattice said.Lattice shares rose 0.4% in after-hours trading after gaining 3.8% in the regular session.
$LSCC
Research
Research Alert: Vertex Reports Mixed Q1, Reaffirms Full-year 2026 Financial Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Vertex delivered mixed Q1 results with revenue of $2.99B (+8% Y/Y) falling $10M short of expectations, though non-GAAP EPS of $4.47 (+10% Y/Y) beat the consensus by $0.16. The quarter demonstrated successful execution of VRTX's multi-product launch strategy, with ALYFTREK generating $424.4M (vs. $53.9M prior year), CASGEVY contributing $42.9M (+202% Y/Y), and JOURNAVX adding $29.0M in its second commercialization year. Recent FDA label extensions for ALYFTREK and TRIKAFTA expanded CF patient eligibility to ~95% in the U.S., adding roughly 800 more patients. VRTX maintained its 2026 guidance unchanged with total revenue expectations of $12.95B-$13.1B and non-CF product revenue of $500M or greater. We view the operating leverage positively, with revenue growth outpacing expense increases, and believe the diversification strategy beyond CF continues to gain traction with meaningful contributions from newly launched therapies across multiple therapeutic areas.
$VRTX